melphalan and Granuloma-Annulare

melphalan has been researched along with Granuloma-Annulare* in 2 studies

Other Studies

2 other study(ies) available for melphalan and Granuloma-Annulare

Article	Year
Orange-yellow diffuse cutaneous eruption in an 82-year-old woman. Archives of dermatology, 2009, Volume: 145, Issue:10 Topics: Aged, 80 and over; Biopsy, Needle; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma Annulare; Humans; Immunohistochemistry; Melphalan; Risk Assessment; Severity of Illness Index; Treatment Outcome; Xanthomatosis	2009
Necrobiotic xanthogranuloma associated with myeloma. Journal of the European Academy of Dermatology and Venereology : JEADV, 2004, Volume: 18, Issue:3 We observed a 73-year-old man with necrobiotic xanthogranuloma (NXG) on the eyelids and concurrent multiple myeloma. The treatment was surgery followed by administration of melphalan. No relapse was seen in 19 months of follow-up. We consider that surgical removal of xanthogranuloma is an advisable rapid treatment that involves fewer side-effects than other treatments. Topics: Aged; Biopsy, Needle; Blood Chemical Analysis; Follow-Up Studies; Granuloma Annulare; Humans; Immunohistochemistry; Male; Melphalan; Multiple Myeloma; Rare Diseases; Risk Assessment; Treatment Outcome; Xanthomatosis	2004

Article

Year

Orange-yellow diffuse cutaneous eruption in an 82-year-old woman.

Archives of dermatology, 2009, Volume: 145, Issue:10

Topics: Aged, 80 and over; Biopsy, Needle; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma Annulare; Humans; Immunohistochemistry; Melphalan; Risk Assessment; Severity of Illness Index; Treatment Outcome; Xanthomatosis

2009

Necrobiotic xanthogranuloma associated with myeloma.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2004, Volume: 18, Issue:3

We observed a 73-year-old man with necrobiotic xanthogranuloma (NXG) on the eyelids and concurrent multiple myeloma. The treatment was surgery followed by administration of melphalan. No relapse was seen in 19 months of follow-up. We consider that surgical removal of xanthogranuloma is an advisable rapid treatment that involves fewer side-effects than other treatments.

Topics: Aged; Biopsy, Needle; Blood Chemical Analysis; Follow-Up Studies; Granuloma Annulare; Humans; Immunohistochemistry; Male; Melphalan; Multiple Myeloma; Rare Diseases; Risk Assessment; Treatment Outcome; Xanthomatosis

2004